Skip to content

Cytek Biosciences, Inc. CTKB Contract Liabilities

Contract Liabilities at other companies

10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$10.14M-19.3%
Bruker logo
BrukerBRKR
$586.1M+1.8%
HTF
Heartflow, Inc. Common StockHTFL
$386K
Danaher logo
DanaherDHR
Agilent Technologies logo
Agilent TechnologiesA
Fortive logo
FortiveFTV

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s contract liabilities?
Cytek Biosciences, Inc. (CTKB) reported contract liabilities of $17.67M in Q1 2026.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.